𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Production of Urokinase-Type Plasminogen Activator (u-PA) and Plasminogen Activator Inhibitor-1 (PAI-1) in Human Brain Tumours

✍ Scribed by Y. Arai; T. Kubota; T. Nakagawa; M. Kabuto; K. Sato; H. Kobayashi

Publisher
Springer Vienna
Year
1998
Tongue
English
Weight
333 KB
Volume
140
Category
Article
ISSN
0001-6268

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR I
TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN RENAL CELL CARCINOMA
✍ WAGNER, STEPHAN N.; ATKINSON, MICHAEL J.; THANNER, STEPHANIE; SCHMITT, MANFRED; πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 597 KB

In experimental models, plasminogen activator-mediated degradation of the extracellular matrix is inhibited by type-1 plasminogen activator inhibitor (PAI-1). PA14 has also been shown to protect tumour stromal tissue from autoproteolytic activities and may thus substantially promote tumour growth an

Staurosporine stimulates expression of t
Staurosporine stimulates expression of the urokinase-type (u-PA) plasminogen activator in LLC-PK1 cells
✍ Christa Dierks-Ventling; Jaromir Knesel; Yoshikuni Nagamine; Brian A. Hemmings; πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 French βš– 959 KB

In LLC-PK, porcine epithelial cells, the urokinase-type plasminogen activator (u-PA) mRNA and protein can be induced either by stimulation of the protein kinase C (PKC) pathway using a tumor promoter (PMA) or by stimulation of the protein kinase A (PKA) pathway with calcitonin SCT). By PKC, to LLC-P